Zeo ScientifiX, Inc. (OTCQB: ZEOX) announced on September 15, 2026, its intention to expand its commercial operations into Georgia and Tennessee. This expansion follows the recent enactment of new state laws in both jurisdictions that establish frameworks for stem cell and regenerative medicine therapies.
The company stated that the move is designed to broaden its presence in the Southeast to support healthcare providers navigating these evolving regulatory environments. The expansion builds upon the company’s existing work with healthcare professionals in Florida, who have utilized the state’s new laws passed in 2025.
Georgia House Bill 1275, signed into law on May 11, 2026, authorizes qualifying human stem cell therapy within the scope established by state law. The legislation includes provisions regarding physician involvement, lawful delegation to licensed practitioners, product sourcing, patient disclosures, informed consent, and oversight.
Tennessee House Bill 2246, signed into law on May 19, 2026, authorizes physicians to perform qualifying stem cell or regenerative medicine therapy within their scope of practice. The law includes statutory requirements for sourcing, documentation, disclosure, informed consent, and adverse-event reporting. Notably, Tennessee’s framework expressly includes certain exosome-based regenerative products within its definition of regenerative medicine therapy when specific criteria are met.
The company emphasized that the state laws do not constitute approval by the U.S. Food and Drug Administration and do not displace applicable federal law. Providers are responsible for ensuring that therapies, products, and clinical protocols comply with all applicable federal, state, and professional requirements.
Zeo ScientifiX intends to support providers in Georgia and Tennessee through scientific and clinical education, product-specific quality and manufacturing documentation, and resources designed to support informed decision-making. The company noted that this approach mirrors its established support model in Florida.
Forward-looking statements in the press release include the company’s expansion plans, anticipated provider support, market development, and the ability to scale its platform as additional states adopt regenerative medicine frameworks.
